The objective response rate (ORR) of the cases with secondary SM who received ALK‐TKI therapy was 88.9%, while the ORR of the patients without secondary SM who received ALK TKI was 20.0% (Table 5). This evidence concerns the gene ALK and systemic mastocytosis.